Nothing Special   »   [go: up one dir, main page]

DK1223930T3 - Behandling af dyskinesi - Google Patents

Behandling af dyskinesi

Info

Publication number
DK1223930T3
DK1223930T3 DK00972966T DK00972966T DK1223930T3 DK 1223930 T3 DK1223930 T3 DK 1223930T3 DK 00972966 T DK00972966 T DK 00972966T DK 00972966 T DK00972966 T DK 00972966T DK 1223930 T3 DK1223930 T3 DK 1223930T3
Authority
DK
Denmark
Prior art keywords
dyskinesia
treatment
compounds
histamine receptor
activation
Prior art date
Application number
DK00972966T
Other languages
English (en)
Inventor
Jonathan Brotchie
Michael Hill
Alan Crossman
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Application granted granted Critical
Publication of DK1223930T3 publication Critical patent/DK1223930T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Resistance Heating (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00972966T 1999-10-22 2000-10-20 Behandling af dyskinesi DK1223930T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924941.9A GB9924941D0 (en) 1999-10-22 1999-10-22 Treatment of dyskinesia

Publications (1)

Publication Number Publication Date
DK1223930T3 true DK1223930T3 (da) 2006-11-20

Family

ID=10863143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00972966T DK1223930T3 (da) 1999-10-22 2000-10-20 Behandling af dyskinesi

Country Status (13)

Country Link
US (1) US7935718B2 (da)
EP (1) EP1223930B1 (da)
JP (1) JP5175015B2 (da)
AT (1) ATE333277T1 (da)
AU (1) AU782357B2 (da)
CA (1) CA2389476C (da)
CY (1) CY1106194T1 (da)
DE (1) DE60029463T2 (da)
DK (1) DK1223930T3 (da)
ES (1) ES2267581T3 (da)
GB (1) GB9924941D0 (da)
PT (1) PT1223930E (da)
WO (1) WO2001030346A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5392770A (en) * 1993-06-29 1995-02-28 Clawson; Burrell E. Tubing circuit systems for humidified respiratory gas
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20080242657A1 (en) * 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
DE102005029468A1 (de) * 2005-06-24 2006-12-28 Plt Patent & Licence Trading Ltd. Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
JP5251870B2 (ja) * 2007-04-24 2013-07-31 東レ株式会社 ジスキネジアの治療または予防剤
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
US5091428A (en) 1987-04-24 1992-02-25 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US5821259A (en) 1991-11-12 1998-10-13 Theoharides; Theoharis C. H3 -receptor agonists as therapeutic agents
WO1993012108A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6028169A (en) 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
GB9815618D0 (en) 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
US6136559A (en) 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
JP4231627B2 (ja) * 1998-10-07 2009-03-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ヒトh3ヒスタミン受容体をコードする単離されたdna
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US6316475B1 (en) 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
US7754210B2 (en) 2002-06-25 2010-07-13 Xu Kai Y Inotropic antibodies and therapeutic uses thereof
CA2498735C (en) 2002-09-13 2011-08-02 Motac Neuroscience Limited Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
DE60313474T2 (de) 2002-09-17 2008-01-03 Motac Neuroscience Ltd. Behandlung von dyskinesie

Also Published As

Publication number Publication date
EP1223930B1 (en) 2006-07-19
DE60029463D1 (de) 2006-08-31
PT1223930E (pt) 2006-12-29
ATE333277T1 (de) 2006-08-15
AU782357B2 (en) 2005-07-21
GB9924941D0 (en) 1999-12-22
JP2003512428A (ja) 2003-04-02
US7935718B2 (en) 2011-05-03
ES2267581T3 (es) 2007-03-16
CA2389476A1 (en) 2001-05-03
US20050245587A1 (en) 2005-11-03
WO2001030346A1 (en) 2001-05-03
AU1152301A (en) 2001-05-08
DE60029463T2 (de) 2007-02-15
JP5175015B2 (ja) 2013-04-03
EP1223930A1 (en) 2002-07-24
CA2389476C (en) 2010-03-09
CY1106194T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
PT1200412E (pt) Agentes anti-proliferativos de imidazole
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
DE50310516D1 (de) Fredericamycin-derivate
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
PL353750A1 (en) Dosages for treatment with anti-erbb2 antibodies
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
DK1096936T3 (da) Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister
CY1106194T1 (el) Θepαπευτικη αγωγη της δυσκινησιας
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
GB0326633D0 (en) Therapeutic agents
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
CY1108628T1 (el) Θεραπεια των κινητικων διακυμανσεων με ενωσεις ενισχυσης της δραστηριοτητας του υποδοχεα 5-υδροξυτρυπταμινη 1α
BR0314540A (pt) Métodos para o tratamento de neurodegeneração
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier